Combination of spironolactone and sitagliptin improves clinical outcomes of outpatients with COVID-19: a prospective cohort study.
M A DavarpanahR AdatorwovorY MansooriF S R RamshehA ParsaM HajianiH FaramarziR KavuluruKamyar AsadipooyaPublished in: Journal of endocrinological investigation (2023)
The combination of sitagliptin and spironolactone reduced duration of COVID infection and hospital visits better than standard therapeutic approaches in outpatients with COVID-19. The effects of combination of sitagliptin and spironolactone in COVID-19 patients should be further verified in a double-blind, randomized, placebo-controlled trial.